BackCyclacel Pharmaceuticals Overview

Cyclacel Pharmaceuticals Long Term Debt

Latest long-term debt for CYCC: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Cyclacel Pharmaceuticals Long Term Debt History

Loading

Cyclacel Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Cyclacel Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cyclacel Pharmaceuticals (CYCC) FAQ

As of the most recent data (June 2026), CYCC shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYCC's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Cyclacel Pharmaceuticals is outperforming or lagging.

Tracking CYCC's long-term debt over time shows whether Cyclacel Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Cyclacel Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Cyclacel Pharmaceuticals's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.